Annals of Oncology

Editorials:

V. C. Jordan

Targeting antihormone resistance in breast cancer: a simple solution
Ann Oncol 14: 969-970; doi:10.1093/annonc/mdg306
[Extract] [FREE Full Text] [PDF] [Request Permissions]

D. Kerr

Europe’s eye is fixed on mighty things
Ann Oncol 14: 971; doi:10.1093/annonc/mdg309
[Extract] [FREE Full Text] [PDF] [Request Permissions]

Special articles:

P. Boyle, P. Autier, H. Bartelink, J. Baselga, P. Boffetta, J. Burn, H. J. G. Burns, L. Christensen, L. Denis, M. Dicato, V. Diehl, R. Doll, S. Franceschi, C. R. Gillis, N. Gray, L. Griciute, A. Hackshaw, M. Kasler, M. Kogevinas, S. Kvinnsland, C. La Vecchia, F. Levi, J. G. McVie, P. Maisonneuve, J. M. Martin-Moreno, J. Newton Bishop, F. Oleari, P. Perrin, M. Quinn, M. Richards, U. Ringborg, C. Scully, E. Siracka, H. Storm, M. Tubiana, T. Tursz, U. Veronesi, N. Wald, W. Weber, D. G. Zaridze, W. Zatonski, and H. zur Hausen

European Code Against Cancer and scientific justification: third version (2003)
Ann Oncol 14: 973-1005; doi:10.1093/annonc/mdg305
[Extract] [FREE Full Text] [PDF] [Request Permissions]

K. M. Tveit

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer
Ann Oncol 14: 1006-1007; doi:10.1093/annonc/mdg297
[Extract] [FREE Full Text] [PDF] [Request Permissions]

L. Sengeløv

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer
Ann Oncol 14: 1008-1009; doi:10.1093/annonc/mdg296
[Extract] [FREE Full Text] [PDF] [Request Permissions]

V. V. Kataja

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer
Ann Oncol 14: 1010-1011; doi:10.1093/annonc/mdg293
[Extract] [FREE Full Text] [PDF] [Request Permissions]

L. M. Jost

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma
Ann Oncol 14: 1012-1013; doi:10.1093/annonc/mdg294
[Extract] [FREE Full Text] [PDF] [Request Permissions]

X. Pivot

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck
Ann Oncol 14: 1014-1015; doi:10.1093/annonc/mdg295
[Extract] [FREE Full Text] [PDF] [Request Permissions]

Reviews:

M. Piccart, L. M. Parker, and K. I. Pritchard

Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
Ann Oncol 14: 1017-1025; doi:10.1093/annonc/mdg290
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

F. Graziano and S. Cascinu

Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough?
Ann Oncol 14: 1026-1038; doi:10.1093/annonc/mdg284
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Original articles:

Hematologic malignancies:

M. A. Dimopoulos, A. Pouli, K. Zervas, V. Grigoraki, A. Symeonidis, P. Repoussis, C. Mitsouli, C. Papanastasiou, D. Margaritis, A. Tokmaktsis, I. Katodritou, G. Kokkini, E. Terpos, N. Vyniou, M. Tzilianos, A. Chatzivassili, M. C. Kyrtsonis, P. Panayiotidis, and A. Maniatis

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma
Ann Oncol 14: 1039-1044; doi:10.1093/annonc/mdg287
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

S. Paydas, K. Tanriverdi, S. Yavuz, U. Disel, B. Sahin, and R. Burgut

Survivin and aven: two distinct antiapoptotic signals in acute leukemias
Ann Oncol 14: 1045-1050; doi:10.1093/annonc/mdg277
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Breast cancer:

L. A. deGraffenried, W. E. Friedrichs, L. Fulcher, G. Fernandes, J. M. Silva, J.-M. Peralba, and M. Hidalgo

Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity
Ann Oncol 14: 1051-1056; doi:10.1093/annonc/mdg291
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

V. Cocquyt, K. Moeremans, L. Annemans, P. Clarys, and S. Van Belle

Long-term medical costs of postmenopausal breast cancer therapy
Ann Oncol 14: 1057-1063; doi:10.1093/annonc/mdg280
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

K. Härtl, W. Janni, R. Kästner, H. Sommer, B. Strobl, B. Rack, and M. Stauber

Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients
Ann Oncol 14: 1064-1071; doi:10.1093/annonc/mdg289
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

K. D. Miller, T. Weathers, L. G. Haney, R. Timmerman, M. Dickler, J. Shen, and G. W. Sledge, Jr

Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
Ann Oncol 14: 1072-1077; doi:10.1093/annonc/mdg300
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Gynecologic tumors:

J. Plisiecka-Halasa, G. Karpinska, T. Szymanska, I. Ziólkowska, R. Madry, A. Timorek, J. Debniak, M. Ulanska, M. Jedryka, A. Chudecka-Glaz, M. Klimek, A. Rembiszewska, E. Kraszewska, B. Dybowski, J. Markowska, J. Emerich, A. Pluzanska, M. Goluda, I. Rzepka-Górska, K. Urbanski, J. Zielinski, J. Stelmachów, M. Chrabowska, and J. Kupryjanczyk

P21^WAF1, P27^KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens
Ann Oncol 14: 1078-1085; doi:10.1093/annonc/mdg299
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

D. Lorusso, G. Ferrandina, S. Greggi, A. Gadducci, S. Pignata, S. Tateo, R. Biamonte, L. Manzione, G. Di Vagno, F. Ferrau’, and G. Scambia

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients
Ann Oncol 14: 1086-1093; doi:10.1093/annonc/mdg301
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, N. Pavlidis, H. P. Kalofonos, H. Gogas, P. Kosmidis, and M. A. Dimopoulos

Phase II study of docetaxel–vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
Ann Oncol 14: 1094-1099; doi:10.1093/annonc/mdg292
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Gastrointestinal tumors:

R. D. Petty, M. C. Nicolson, S. Skaria, T. S. Sinclair, L. M. Samuel, and M. Koruth

A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity
Ann Oncol 14: 1100-1105; doi:10.1093/annonc/mdg278
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

K. Bouzid, S. Khalfallah, J. Tujakowski, B. Piko, G. Purkalne, S. Plate, P. Padrik, M. Serafy, E. M. Pshevloutsky, and B. Boussard

A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer
Ann Oncol 14: 1106-1114; doi:10.1093/annonc/mdg288
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

T. W. Kim, H. M. Chang, H. J. Kang, J. R. Lee, M. H. Ryu, J. H. Ahn, J. H. Kim, J. S. Lee, and Y. K. Kang

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer
Ann Oncol 14: 1115-1120; doi:10.1093/annonc/mdg281
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

J. Aparicio, J. M. Vicent, I. Maestu, S. Garcerá, I. Busquier, C. Bosch, C. Llorca, R. Díaz, C. Fernández-Martos, and A. Galán

Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer
Ann Oncol 14: 1121-1125; doi:10.1093/annonc/mdg285
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Sarcomas:

G. Bacci, A. Briccoli, M. Rocca, S. Ferrari, D. Donati, A. Longhi, F. Bertoni, P. Bacchini, S. Giacomini, C. Forni, M. Manfrini, and S. Galletti

Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide
Ann Oncol 14: 1126-1134; doi:10.1093/annonc/mdg286
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Miscellaneous tumors:

M. Cimitan, A. Buonadonna, R. Cannizzaro, V. Canzonieri, E. Borsatti, R. Ruffo, and L. De Apollonia

Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role
Ann Oncol 14: 1135-1141; doi:10.1093/annonc/mdg279
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Phase I and pharmacokinetics:

G. F. Fleming, R. L. Schilsky, L. P. Schumm, A. Meyerson, A. M. Hong, N. J. Vogelzang, and M. J. Ratain

Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction
Ann Oncol 14: 1142-1147; doi:10.1093/annonc/mdg302
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

M. J. Quinn, A. d’Onofrio, B. Møller, R. Black, C. Martinez-Garcia, H. Møller, M. Rahu, C. Robertson, L. J. Schouten, C. La Vecchia, and P. Boyle

Cancer mortality trends in the EU and acceding countries up to 2015
Ann Oncol 14: 1148-1152; doi:10.1093/annonc/mdg307
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Letters to the Editor:

M. Eck, B. Schmausser, T. Kerkau, A. Greiner, M. Kraus, W. Fischbach, and H. K. Müller-Hermelink

Autoantibodies in gastric MALT-type lymphoma
Ann Oncol 14: 1153-1154; doi:10.1093/annonc/mdg304
[Extract] [FREE Full Text] [PDF] [Request Permissions]

M. Velasco-Garrido and R. Busse

Whose ‘wish bias’?
Ann Oncol 14: 1154; doi:10.1093/annonc/mdg303
[Extract] [FREE Full Text] [PDF] [Request Permissions]

R. Fossati, C. Confalonieri, G. Apolone, S. Cavuto, and S. Garattini

Reply to Letter to the Editor "Whose ‘wish bias’?", by M. Velasco-Garrido & R. Busse (Ann Oncol 2003; 14: 1154)
Ann Oncol 14: 1154-1155; doi:10.1093/annonc/mdg282
[Extract] [FREE Full Text] [PDF] [Request Permissions]

M. Balzarotti, M. Magagnoli, and A. Santoro

Early restaging positron emission tomography with ¹⁸F-fluorodeoxyglucose in aggressive non-Hodgkin’s lymphomas: is it too easy to be true?
Ann Oncol 14: 1155-1156; doi:10.1093/annonc/mdg283
[Extract] [FREE Full Text] [PDF] [Request Permissions]

A. Bottini, L. Dogliotti, A. Bersiga, M. P. Brizzi, and A. Berruti

p53 expression and disease outcome of breast cancer patients undergoing primary chemotherapy with anthracycline-containing regimens
Ann Oncol 14: 1156; doi:10.1093/annonc/mdg298
[Extract] [FREE Full Text] [PDF] [Request Permissions]

Book reviews:

X. Cathelineau

P.W. Kantoff, P.R. Carroll, A.V. D'Amico (eds). Prostate Cancer: Principles and Practice
Ann Oncol 14: 1157; doi:10.1093/annonc/mdg276
[Extract] [FREE Full Text] [PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.